Introduction
Triple plays are rare both in baseball and investing. Recently, I was lucky enough to enjoy a triple when ImmunoGen (IMGN) reported stellar results from a phase 1 trial for a cancer therapy. This article will look into how and if I can successfully build a new winning position in this stock.
One of my best moves in recent times was to follow the advice of Hawkinvest at year end 2016 to buy ImmunoGen below $2.00.
I was scanning SA for interesting prospects during the waning hours of 2016. Fortune shown on me when I encountered Hawkinvests's article: "ImmunoGen: Why This Neglected $1 Biotech Stock Is A Strong Buy Now". I had low expectations when I started the article.
